Table 2.

Relative risk, hazard ratio, and absolute risk reduction of molnupiravir use on post-acute sequelae of covid-19, post-acute death, post-acute hospital admission, and composite outcome of post-acute death or hospital admission compared with no treatment

Outcome	Estimate (95% CI)	Event rate (%) at 180 days (95% CI)		Absolute risk reduction (%) at 180 days (95% CI)
		Molnupiravir group*	No treatment group†
Post-acute sequalae of covid-19	RR 0.86 (0.83 to 0.89)	18.58 (17.94 to 19.24)	21.55 (21.04 to 22.07)	2.97 (2.31 to 3.60)
Post-acute death	HR 0.62 (0.52 to 0.74)	1.44 (1.20 to 1.69)	2.32 (2.24 to 2.39)	0.87 (0.62 to 1.13)
Post-acute hospital admission	HR 0.86 (0.80 to 0.93)	8.82 (8.24 to 9.40)	10.15 (10.00 to 10.29)	1.32 (0.72 to 1.92)
Post-acute death or hospital admission	HR 0.82 (0.77 to 0.88)	9.65 (9.05 to 10.26)	11.65 (11.50 to 11.80)	2.00 (1.37 to 2.62)

CI=confidence interval; HR=hazard ratio; RR=relative risk.

Post-acute outcomes were ascertained 30 days after the first SARS-CoV-2 positive test result between 5 January 2022 and 15 January 2023 until end of follow-up.

^*Received prescription for molnupiravir within five days after testing positive for SARS-CoV-2 and did not use any other outpatient antiviral or antibody during first 30 days after testing positive.

^†Did not use any outpatient antiviral or antibody during first 30 days after testing positive for SARS-CoV-2 and served as reference group in analyses.